MX2007014652A - Compositions and methods of treating retinal disease - Google Patents
Compositions and methods of treating retinal diseaseInfo
- Publication number
- MX2007014652A MX2007014652A MXMX/A/2007/014652A MX2007014652A MX2007014652A MX 2007014652 A MX2007014652 A MX 2007014652A MX 2007014652 A MX2007014652 A MX 2007014652A MX 2007014652 A MX2007014652 A MX 2007014652A
- Authority
- MX
- Mexico
- Prior art keywords
- aryl
- carbamoyl
- hydroxyl
- compound
- compound according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 201000011056 retinal disease Diseases 0.000 title claims abstract description 33
- 208000002780 Macular Degeneration Diseases 0.000 claims abstract description 57
- 238000009825 accumulation Methods 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims description 271
- 125000000217 alkyl group Chemical group 0.000 claims description 148
- 239000011604 retinal Substances 0.000 claims description 110
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 109
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 100
- 125000003118 aryl group Chemical group 0.000 claims description 90
- -1 aminosulfonylamino Chemical group 0.000 claims description 76
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- 125000003282 alkyl amino group Chemical group 0.000 claims description 65
- 125000005843 halogen group Chemical group 0.000 claims description 63
- 229910052736 halogen Inorganic materials 0.000 claims description 61
- 150000002367 halogens Chemical class 0.000 claims description 59
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 58
- 125000001424 substituent group Chemical group 0.000 claims description 57
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 47
- 125000005842 heteroatoms Chemical group 0.000 claims description 41
- 239000011780 sodium chloride Substances 0.000 claims description 37
- 125000004414 alkyl thio group Chemical group 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 229940079593 drugs Drugs 0.000 claims description 33
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 33
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 33
- 125000004434 sulfur atoms Chemical group 0.000 claims description 33
- 125000004429 atoms Chemical group 0.000 claims description 32
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 32
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 32
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 32
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 26
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 25
- 239000002262 Schiff base Substances 0.000 claims description 23
- 150000004753 Schiff bases Chemical class 0.000 claims description 23
- 239000000460 chlorine Substances 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrugs Drugs 0.000 claims description 18
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 17
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 16
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 230000002207 retinal Effects 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 11
- 150000001555 benzenes Chemical group 0.000 claims description 10
- FQZJYWMRQDKBQN-UHFFFAOYSA-N Tricaine mesylate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 210000001519 tissues Anatomy 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 6
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002835 absorbance Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960005274 Benzocaine Drugs 0.000 claims description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 3
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthocaine Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 claims description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 3
- ZMCBYSBVJIMENC-UHFFFAOYSA-N Tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 claims description 3
- 229950006098 orthocaine Drugs 0.000 claims description 3
- 229960004919 procaine Drugs 0.000 claims description 3
- RWZYAGGXGHYGMB-UHFFFAOYSA-M anthranilate Chemical compound NC1=CC=CC=C1C([O-])=O RWZYAGGXGHYGMB-UHFFFAOYSA-M 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229940072040 tricaine Drugs 0.000 claims description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 37
- 238000005755 formation reaction Methods 0.000 abstract description 32
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 80
- 235000020945 retinal Nutrition 0.000 description 79
- 230000000007 visual effect Effects 0.000 description 38
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 210000003583 Retinal Pigment Epithelium Anatomy 0.000 description 34
- 201000010099 disease Diseases 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 31
- 210000004027 cells Anatomy 0.000 description 26
- 206010064930 Age-related macular degeneration Diseases 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 102000010175 Opsin Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 125000004432 carbon atoms Chemical group C* 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000004438 eyesight Effects 0.000 description 12
- 230000004301 light adaptation Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 108020000793 RHO Proteins 0.000 description 11
- 210000001525 Retina Anatomy 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 210000004379 Membranes Anatomy 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 230000002132 lysosomal Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 206010062766 Stargardt's disease Diseases 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 230000000670 limiting Effects 0.000 description 8
- 238000003419 tautomerization reaction Methods 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 102100011470 ABCA4 Human genes 0.000 description 7
- 210000003712 Lysosomes Anatomy 0.000 description 7
- 125000003172 aldehyde group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000004300 dark adaptation Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000001868 lysosomic Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229940012356 Eye Drops Drugs 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 108091008017 photoreceptors Proteins 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 101700012451 ABCA4 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 230000002633 protecting Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 229960003471 retinol Drugs 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- VAMXMNNIEUEQDV-UHFFFAOYSA-N Methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 4
- 208000001140 Night Blindness Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229940045997 Vitamin A Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000006242 amine protecting group Chemical group 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000002569 neurons Anatomy 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000000750 progressive Effects 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010008148 Member 4 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 description 3
- 108050001704 Opsin Proteins 0.000 description 3
- 231100000614 Poison Toxicity 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 3
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 3
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000003444 anaesthetic Effects 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 3
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 125000004986 diarylamino group Chemical group 0.000 description 3
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 3
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 230000000448 retinotoxic Effects 0.000 description 3
- 231100000390 retinotoxic Toxicity 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 102100004996 ATP12A Human genes 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- 229940088623 Biologically Active Substance Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical group [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 235000019169 all-trans-retinol Nutrition 0.000 description 2
- 239000011717 all-trans-retinol Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000004569 blindness Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003412 degenerative Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000002587 enol group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 150000002466 imines Chemical group 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229940102398 methyl anthranilate Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000004297 night vision Effects 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 238000007699 photoisomerization reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004262 retinal health Effects 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001340 slower Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 230000002463 transducing Effects 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 230000035513 volume of distribution Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- SHGAZHPCJJPHSC-XFYACQKRSA-N (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 1
- OBSLWIKITOYASJ-YDEIVXIUSA-N (3R,4R,5S,6R)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical compound CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 1
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-M 1,3-thiazole-4-carboxylate Chemical compound [O-]C(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-M 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- SCXZSBFGBBJQQC-UHFFFAOYSA-N 2-aminopropane-1,1,1-triol Chemical compound CC(N)C(O)(O)O SCXZSBFGBBJQQC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- PWBIAEVWEMNPLY-UHFFFAOYSA-N 3-methylsulfonylthiophene Chemical compound CS(=O)(=O)C=1C=CSC=1 PWBIAEVWEMNPLY-UHFFFAOYSA-N 0.000 description 1
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3H-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000001775 Bruch Membrane Anatomy 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101700067048 CDC13 Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical class [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000003855 Cell Nucleus Anatomy 0.000 description 1
- 210000003986 Cell, Retinal Photoreceptor Anatomy 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 210000004087 Cornea Anatomy 0.000 description 1
- 229940104302 Cytosine Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 241000765600 Drusus Species 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 210000001723 Extracellular Space Anatomy 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 240000004119 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N N-(benzenesulfonyl)-N-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010073310 Occupational exposure Diseases 0.000 description 1
- 229940069265 Ophthalmic Ointment Drugs 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- VEDDBHYQWFOITD-UHFFFAOYSA-N Para-Bromobenzyl Alcohol Chemical compound OCC1=CC=C(Br)C=C1 VEDDBHYQWFOITD-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 210000000608 Photoreceptor Cells Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 210000001116 Retinal Neurons Anatomy 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N Sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 210000000538 Tail Anatomy 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N Tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- 229940013180 Tricaine methanesulfonate Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-L acetate;hydroxide Chemical compound [OH-].CC([O-])=O PQLVXDKIJBQVDF-UHFFFAOYSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 235000019194 all-trans-retinaldehyde Nutrition 0.000 description 1
- 239000011751 all-trans-retinaldehyde Substances 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940054051 antipsychotic Indole derivatives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 230000004371 high visual acuity Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940021222 peritoneal dialysis Isotonic solutions Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004437 phosphorous atoms Chemical group 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003334 potential Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 230000001698 pyrogenic Effects 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000036633 rest Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000946 synaptic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Abstract
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
Description
COMPOSITIONS AND METHODS TO TREAT RETINAL DISEASE
FIELD OF THE INVENTION This application is related to compositions and methods for treating macular degeneration and other forms of retinal disease, whose etiology involves the accumulation of
A2E and / or lipofuscin in the retinal tissue, more specifically, to avoid the accumulation of A2E.
BACKGROUND OF THE INVENTION Two forms of retinal disease include Stargardt's disease, which afflicts young adults and age-related macular degeneration (AMD), which afflicts adults in middle life or later. Both forms are characterized by the progressive degeneration of the conical photoreceptors located in the region of the macular fossa, degeneration which leads to the loss of high acuity of vision in the central visual field. The disease has been associated with the accumulation of toxic biochemicals, including lipofuscin, within the cells of the retinal pigment epithelium (RPE) and extracellular druse, where the RPE cells are in contact with the Bruch membrane. The accumulation of these retinotoxic mixtures is one of the most important risk factors in the etiology of AMD. AMD begins as a "dry form" without vascular complications. Currently there are no known treatments for the dry form of AMD. A patient of ten progresses to a late-stage form of the disease, known as "wet form" AMD, which is characterized by
choroidal neovascularization that invades the macula and breaks the retinal and RPE tissue. AMD treatments of the most common wet form suppress vascular growth or inflammatory processes. During the normal visual cycle (summarized in Figure
1), most of the trans-RAL is sequestered by the opsin proteins in the disc membranes of the outer segment of the photoreceptor. This mechanism of sequestration protects the trans-RAL group from reacting with the phosphatidylethanolamine (PE) before the trans-RAL dehydrogenase (RDH) converts the trans-RAL to the alcohol trans-retinol. Some trans-RAL molecules escape sequestration, however, and react with phosphatidylethanolamine to first form N-retinylidene-phosphatidylethanolamine (APE) and then N-retinylidene-N-retinyl-phosphatidylethanolamine (A2PE) in the disks of the external segments of the photoreceptor. Both A2PE and trans-RAL that have escaped sequestration are transported out of the photoreceptor disk membranes by an ATP binding cassette transporter, called Rim protein (RmP) or ABCA4 (formerly ABCR). After this transport, the trans-RAL is reduced to trans-retinol by RDH and crosses the plasma membrane of the outer segment (OS) to the extracellular space, where it is captured by the cells of the retinal pigment epithelium (RPE). A2PE is captured by the lysosomes of the RPE cells when the RPE cells ingest the outer segments of the photoreceptor that are released routinely. Once inside the lysosomes, the A2PE becomes irreversibly converted to A2E, which causes the lysosomal failure. Lysosomal failure poisons RPE cells and compromises their ability to provide biochemical support to
the photoreceptors of the retina, leading to the progressive degeneration of both cell types. Multiple factors affect the speed of the accumulation of A2E, both genetic and environmental. For example, a hereditary mutation in both copies of the ABCA4 transporter gene increases the accumulation of A2E and leads to Stargardt disease in children and young adults. A late-onset form of Stargardt's disease is associated with ABCA4 mutations that are more benign. Many think that Stargardt's disease is an early onset form of AMD, where the normal age-related accumulation of A2E is accelerated by the ABCA4 mutation to a degree sufficient for the disease to be triggered decades before the AMD appears normally. With respect to environmental factors, it is well established in animal models that the speed of formation of the A2E varies with exposure to light. It has been shown that a fatty acid (phosphatidylglycerol) can protect RPE cells from cell death induced by A2E, and that other dietary factors can influence the progression of the disease, including zinc (which affects the activity of retinol oxidoreductase). There is a need for effective treatments of AMD in dry form and Stargardt's disease, which stop the progression of the disease and preserve or restore vision.
SUMMARY OF THE INVENTION The invention relates to compositions and methods for treating macular degeneration and other forms of retinal disease, the etiology of which involves the accumulation of
A2E and / or lipofuscin in the retinal tissue. In one embodiment, the present invention provides compositions and methods for treating macular degeneration and other retinal disease with an etiology involving the accumulation of A2E and / or lipofuscin, limiting the formation of cytotoxic A2E. For example, the formation of A2E is avoided or reduced by limiting the amount of trans-RAL not sequestered for reaction with phosphatidyl ethanolamine (PE) in the outer segments of the photoreceptor. In one method, a therapeutic compound, i.e., a "RAL collector" is administered to a patient, whereby the drug competes with the PE for the trans-RAL, forming an adduct of a Schiff's base. "Free RAL" is defined as the RAL that is not linked to a protein of the visual cycle. In another embodiment, the invention relates to a method for identifying a drug for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, which may include administering a candidate agent to a subject having , or is at risk of developing macular degeneration and retinal disease, and measuring the formation of A2E in the presence of the candidate agent, in relation to the formation of A2E in the absence of the candidate agent. A wide variety of drugs is contemplated for use in the methods of the invention. In some embodiments, inhibitors of A2E formation include RAL collectors. For example, the pharmacological objective of such RAL collector compounds is trans-RAL, which has escaped from sequestration by opsins in the outer segments of the photoreceptor. RAL collectors include, for example, cyclic amines and heterocyclic amines of five and
six members having one or more pairs of conjugated double bonds, and for example, can be aromatic. In some embodiments, the RAL collector is administered to a subject as a topical formulation for delivery by drops for the os or via a skin patch. The invention relates to a method for treating or preventing macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin in a subject, the method is by administering a composition that reduces the level of accumulation of A2E in relation to the level of accumulation of A2E in the subject, without the administration of the composition. The invention also relates to a method for treating or preventing macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin in a subject, by administering to the subject a composition that reduces the level of formation of A2E in relation to the level of A2E formation in the subject without the administration of the composition. In some embodiments, the methods of the invention further include, diagnosing macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin in the subject. In other modalities, the methods also include monitoring macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscma in the subject. In one aspect, the invention relates to the administration of a composition that includes a compound selected from benzocaine, procaine, orthocaine, tricaine (MS222, compound 6) and methyl anthranilate.
In one aspect, the methods of the invention include administering a composition that includes a compound of the
Formula IV:
IV, wherein X is O, N (H) or S, het is a 5- or 6-membered heterocycle, n is 0, 1, 2 or 3, and each D is an unbranched lower alkyl group. Each D can be the same or different. In one modality, the D's are the same. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino;
(N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In one embodiment, each D is methyl. In some embodiments, the substituents (U) are selected such that the first pKa of the NH2 ring is about 3.5. In one aspect, the methods of the invention include administering a composition that includes a compound of formula I:
I, wherein, W, X, Y and Z are each, independently, N, S, O, CU or CH, and at least one of W, X, Y and Z is N; n is 0, 1, 2, 3 or 4, A is
; D is unbranched lower alkyl, R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a branched or unsubstituted alkyl chain, branched, of C3, C4, C5, C6, C7 or C8. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom,
hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In one embodiment, the identity of W, X, Y and Z is such that the compound comprises a ring of pyridine, pyridazine or pyrazine. In some modalities, U is aryl. For example, U can be benzene. U can also be benzene substituted with halo.
In some modalities, A is
In some
modalities, A is
and D is methyl In some embodiments, two adjacent U substituents are connected to form a 5 or 6 member ring optionally substituted. For example, the substituents can be connected to form a benzene ring, forming a compound having the structure according to the formula:
wherein, X, Y and Z are each, independently, N, O, S, CH or are absent, so that at least one of X, Y and Z is N; p is 0, 1, 2 or 3, B is a halogen atom, hydroxyl, carbamoyl, substituted or unsubstituted aryl or amino, A is
; D is unbranched lower alkyl, R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a branched or unsubstituted alkyl chain, branched, of C3, C4, C5, C6, C7 or C8. The compounds of Formula 1 may include:
In one modality, the composition used in the
methods of the invention includes the compound
or a pharmaceutically acceptable salt thereof. In one aspect, the methods of the invention include administering a composition that includes a compound of formula II or Ha:
one, independently, N or NH, S, 0, CU or CH, so that at least one of Q, T and V is not CU or CH; the dotted line represents two double bonds within the ring, which meets the valence requirements of the atoms and heteroatoms present in the ring; m is 0, 1 or 2; A is
; D is unbranched lower alkyl, R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, Cß, C7 or C8, or a branched or unsubstituted alkyl chain, branched, of C3, C4, C5, Cß, C7 or C8. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen atom,
hydroxyl, carbamoyl, aryl and amino; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; and (sic)
In one embodiment, in the compounds of formula II or II, U is aryl. For example, U can be benzene. U may also be a benzene ring substituted with halo. In some embodiments, in the compounds of formula
II or Ha, A is
In some compounds, each D is methyl. In one embodiment, in the compounds of formula II or Ha, Q, T and V are selected such that the composition includes a furan or thiophene ring. In one embodiment, in the compounds of formula II or Ha, U is lower alkyl. For example, U can be methyl. In one embodiment, in the compounds of formula II or Ha, U is a halogen atom. For example, U can be fluorine or chlorine. An example of a composition useful in the methods of
the invention includes the compound
, or a pharmaceutically acceptable salt thereof. In one aspect, the methods of the invention include administering a composition that includes a compound of formula III:
I? , where L is a bond or CH2; A is
; D is unbranched lower alkyl, R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, Cß, C7 or C8, or a branched or unsubstituted alkyl chain, branched, of C3, C4, C5, Cß, C7 or C8 and k is 0, 1, 2, 3 or 4. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-alkylamino
lower; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino;
(N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In some embodiments, in the compounds of formula
III, A is
In some compounds, each D is methyl. In some embodiments, in the compounds of formula III, U is aryl. For example, U can be benzene. In some embodiments, U is a benzene ring substituted with halo. In one aspect, the methods of the invention include administering a composition that includes a compound of formula III, wherein two adjacent U substituents are connected to form a 5 or β-member ring, optionally substituted. For example, the methods of the invention include administering a composition that includes a compound of formula III, wherein the adjacent U substituents are connected as a heterocyclic ring, forming a compound having the structure according to the formula Illa:
where L is a single bond or CH2,
X, Y and Z with each one, independently, N, NH, O, S,
CB, CH or are absent, so that at least one of X, Y and Z is N or NH; p is 0, 1, 2 or 3; B is a halogen, hydroxyl, carbamoyl, aryl or amino atom; A is
; D is unbranched lower alkyl, R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, Cß, C7 or C8, or a branched or unsubstituted alkyl chain, branched, of C3, C4, C5, Cß, C7 or C8. In one embodiment, in the compound of formula Illa, the fused heterocyclic ring is a 6-membered ring. For example, the ring may be a pyridine ring. In one embodiment, in the compound of formula Illa, the fused heterocyclic ring is a 5-membered ring. For example, the ring can be a thiazole, oxazole or imidazole. In one embodiment, in the compound of formula Illa, B is aryl. For example, B is benzene. In one embodiment, the methods of the invention include administering a composition that includes a compound
selected from
or pharmaceutically acceptable salts thereof. In one aspect, methods of the invention include chronically administering a composition to treat or prevent macular degeneration and other forms of disease.
retinal whose etiology involves the accumulation of A2E and / or lipofuscin. In one aspect, the invention also relates to a method for identifying a drug to treat or prevent macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, by administering a candidate drug to a subject that has, or is at risk of developing macular degeneration or other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin; and measuring the accumulation of A2E in the subject; wherein the reduced accumulation of A2E in the presence of the candidate drug in relation to the accumulation of A2E in the absence of the candidate drug indicates that the candidate drug is a drug to treat or prevent macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin. In another aspect, the invention relates to a method for identifying a drug to treat or prevent macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, by: contacting an in vitro model of the visual cycle with the candidate drug; and measure the accumulation of A2E; wherein the reduced accumulation of A2E in the presence of the candidate drug in relation to the accumulation of A2E in the absence of the candidate drug indicates that the candidate drug is a drug to treat or prevent macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin. The present invention relates to compounds and their use to treat macular degeneration, including the form
dryness of AMD and Stargardt's disease, and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin. An aspect of the invention includes a compound of formula I, II, Ha, III, Illa or IV, wherein the adduct of the Schiff Base of the compound and 11-cis-RAL, have an extinction coefficient equal to , or less than that of free 11-cis-RAL. In one embodiment, the absorbance peak of the Schiff Base adduct is at a wavelength equal to or less than that of free 11-cis-RAL. Another aspect of the invention includes a compound that
has the formula IV: (IV), where X is O, N (H) or
S and het is a 5- or 6-membered heterocycle, n represents 0, 1, 2 or 3, and each D is an unbranched lower alkyl group. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl;
lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino;
(N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In another modality, each D is methyl. In another embodiment, the pKa of the NH2 ring
(NH2 - »NH) is approximately 3.5. Another aspect of the invention includes a compound
represented by the general formula I: (I). W,
X, Y and Z are each, independently, N, S, O, CU or CH, such that at least one of, X, Y and Z is N. A is
D is unbranched lower alkyl. R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, Cβ, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, Cß , C7 or C8. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are
optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. n represents 0, 1, 2, 3 or 4. In one embodiment, the compound comprises a ring of pyridine, pyridazine or pyrazine. In another embodiment, U is an aryl. In another embodiment, U is a benzene. In another embodiment, U is a benzene substituted with
halo, In one modality, A is
and D is methyl. In
another embodiment, two adjacent U substituents are connected to form an optionally substituted 5 or β-member ring. In another embodiment, two adjacent U substituents are connected to a benzene ring, forming a compound having the structure according to the formula:
(the) . X, Y and Z are each, independently, N, O, S, C (H) or absent, so that at least one of X, Y and Z is N. p is 0, 1, 2 or 3. B is a halogen, hydroxyl, carbamoyl, aryl or amino atom. A is
D is unbranched lower alkyl. R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, Cβ, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, Cß , C7 or C8. In one embodiment, the composition comprises a compound selected from:
In a modality
In addition, the compound is selected from pharmaceutically acceptable salts thereof. Another aspect of the invention includes a compound represented by formula II or II:
he has) . Q, T and V are each, independently, N (H), S, O, CU or CH, so that at least one of Q, T and V is not CU or CH. The ring in dotted lines represents two double bonds within the ring, which meets the valence requirements of the atoms and heteroatoms present in the ring, m is 0, 1 or 2. A is
D is unbranched lower alkyl. R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, Cβ, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, Cß , C7 or C8. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more atoms of
hydrogen in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In one embodiment, U is an aryl. In another embodiment, U is a benzene. In another embodiment, U is a benzene substituted with halo. In a
modality, A is
. In another modality, each D is methyl. In another embodiment, Q, T and V are selected such that the composition comprises a furan or thiophene ring. In another embodiment, U is lower alkyl. In another embodiment, U is methyl. In another embodiment, U is a halogen atom. In another modality, U is fluorine. In an additional mode, the
The compound is selected from and pharmaceutically acceptable salts thereof. Another aspect of the invention includes a compound
represented by general formula III:
III L is a single bond or CH2. A is
D is unbranched lower alkyl. R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, Cβ, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, Cß , C7 or C8. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are
optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino;
(N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. k is
0, 1, 2, 3 or 4. In one modality, A is
In another modality, each D is methyl. In another embodiment, U is an aryl. In another embodiment, U is a benzene. In another embodiment, U is a benzene substituted with halo. In another embodiment, two adjacent U substituents are connected to form an optionally substituted 5 or β-member ring. In another embodiment, two adjacent U substituents are connected as a heterocyclic ring, forming a compound having the
structure according to the Illa formula:
(Illa) X, Y and Z are each, independently, N, O,
S, CB, CH or are absent, so that at least one of X, Y
and Z is N. p is 0, 1, 2 or 3. B is a halogen, hydroxyl, carbamoyl, aryl or amino atom. A is
D is unbranched lower alkyl. R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, Cβ, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, Cß , C7 or C8. In one embodiment, the fused ring is a 6-membered ring. In another embodiment, the fused heterocyclic ring is a pyridine ring. In another embodiment, the fused heterocyclic ring is a 5-membered ring. In another embodiment, the fused heterocyclic ring is selected from thiazole, oxazole and imidazole. In another embodiment, B is aryl. In another embodiment, B is benzene. In another embodiment, the compound is selected from
J and pharmaceutically acceptable salts thereof. Pharmaceutical compositions that include a compound of Formula I, II, Ha, III, Illa or IV or a pharmaceutically acceptable salt thereof, are used in the methods of the invention. In one embodiment, the compound of Formula I, II, Ha, III, Illa or IV or a pharmaceutically acceptable salt thereof is coadministered with one or more additional therapies. The above description fairly broadly discloses the most important features of the present invention,
in order that the detailed description of the same that follows may be understood, and in order that the present contributions to the art may be better appreciated. Other objects and features of the present invention will become apparent from the following detailed description, considered in conjunction with the examples.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a diagram of the visual cycle. Figure 2 is a schematic of the reaction path of the formation of A2E. Figure 3 is a schematic of the formation of the Schiff base. Figure 4a is a UV-vis spectrum of compound 6 and RAL; Figure 4b is a graph of the formation of the adduct of a Schiff base. Figure 5 is a graph of the standard curve for the ERG measurement of the retinal responses to experimental stimuli of variable light intensity. Figure 6a is a graph of the ERG measurement of the dark adaptation rate of a photodecided rat during anesthesia, and Figure 6b is a graph of the EGR measurement of the dark adaptation of a photodecolorated rat without anesthesia. Figure 7 is a graph of the effect of compound 6 on the ERG light sensitivity of a rat adapted to darkness. Figure 8 is a graph showing the reaction kinetics of RAL-compound 8 by NMR.
DETAILED DESCRIPTION OF THE INVENTION
The present application provides compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, for example, by limiting the formation of cytotoxic A2E. The formation of A2E can be avoided or reduced by limiting the amount of trans-RAL available for the reaction with phosphatidyl ethanolamine (PE). The progressive accumulation of A2E in RPE cells causes dry AMD. By reducing the amount of accumulation of A2E, the present invention prevents the onset and / or progression of dry AMD. In one procedure, a small molecule drug is administered, which competes with the PE for reaction with trans-RAL that has escaped sequestration by the opsins in the outer segments of the photoreceptor. As shown in Figure 2, the RAL contains an aldehyde group. The aldehyde group stabilizes the binding of 11-cis-RAL to the photoreceptor membrane protein called opsin, forming a Schiff base (Figure 3) with an amino acid side chain at the opsin binding site. Opsin releases the trans-RAL from this binding site after transducing the photoisomerization of the 11-cis-RAL bound through a second messenger path. Although the aldehyde group in the RAL is a useful molecular anchor for the binding of opsin, it is otherwise dangerous due to the reactivity of its Schiff base with other biological amines. To mitigate this risk, the visual cycle proteins have developed molecular mechanisms to continuously sequester the RAL molecules, and thus protect the aldehyde group from the lateral chemical reactions. However, these mechanisms that sequester proteins are not completely reliable.
Over time, as much as a trans-RAL molecule of three, it escapes the sequestration of proteins, where it is free to initiate a cascade of reactions that begins with the formation of A2PE in the outer segments of the photoreceptor and culminates in the formation of A2E in the lysosomes of RPE cells. Once formed in the lysosomes of the RPE cells, A2E inhibits the proton pump activated by ATP in the lysosome membranes and causes the lysosomal pH to increase. The increase in pH deactivates acid hydrolases and therefore causes lysosomal failure. Lysosomal failure is also caused by the detergent action of A2E, which solubilizes lysosomal membranes. Lysosomal failure poisons RPE cells and compromises their ability to provide biochemical support to retinal photoreceptors, leading to progressive degeneration of both cell types and visual impairment. The aromatic hydroxyl amine and amine compounds were described as aldehyde nucleophiles in the reactions of the Schiff base with the RAL by Hubbard in 1956. Hubbard, J. Am. Chem. Soc. 78: 4662, 1956; see also Rapp and Basinger, Vision Res. 22: 1097, 1982, and Fole et al, J. Photochem. Photobiol B8: 183, 1991. Two such compounds that have a history of insurance for human use for other purposes include methyl anthranilate, a natural product found in grapes, and MS-222, a fish anesthetic used by fish breeders who are exposed to it professionally, during the handling of the fish. However, MS-222 is pharmacologically active in the human retina and has no anesthetic activity in mammals.
In 1963, Do ling showed that anesthetics decrease the regeneration of rhodopsin and adaptation to darkness in rats. This was the first report that such small molecules could modulate retinal visual performance. Dowling, J. Gen. Physiol. 46: 1287, 1963. In 1982,
Rapp & Basinger showed that certain local anesthetics form the basis of Schiffs with RAL and slow the adaptation to darkness in frogs. This was the first elucidation of the mechanism of the chemical reaction by which these compounds modulate retinal visual performance. Rapp and Basinger, Vision Res. 22: 1097, 1982. In 1997, Bernstein et al., Showed that MS222 (6) reversibly attenuates night vision in humans with occupational exposure. This was the first report that such a compound can be absorbed through the skin and reversibly modulate human retinal vision without known side effects. Bernstein et al, Am. J. Opthalmol, 124: 843, 1997.
Definitions For convenience, before further description of exemplary modalities, certain terms used in the specification, examples and appended claims are collected here. These definitions should be read in light of the rest of the description and as understood by a person skilled in the art. The articles "a" and "an" are used herein to refer to one or more than one (ie, at least one) of the grammatical object of the article. By way of example, "an element" means an element or more than one element. The terms "comprises," "comprising," "includes,"
"that includes," "has," and "that has" are used in the inclusive, open sense, meaning that additional elements may be included. The terms "such as", "for example", as used herein, are non-limiting and are for illustrative purposes only. "Including" and "including non-exclusively" are used interchangeably. The term "or" as used herein shall be understood to mean "and / or", unless the context clearly dictates otherwise. In the present specification, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present invention includes all isomers such as geometric isomers, optical isomers based on an asymmetric carbon, stereoisomer, tautomer and the like, which may occur structurally and a mixture of isomers and is not limited to the description of the formula for convenience, and may be any of an isomer or a mixture. Therefore, an asymmetric carbon atom may be present in the molecule and an optically active compound and a racemic compound may be present in the present compound, but the present invention is not limited thereto and includes any. In addition, a crystalline polymorphism may be present, but is not limiting, but any crystalline form may be a single crystal or a mixture of a crystalline form, or an anhydride or hydrate. In addition, the so-called metabolite that is produced by the degradation of the present compound in vivo is included within the scope of the present invention. It will be noted that the structure of some of the compounds of the invention include asymmetric (chiral) carbon atoms. It will be understood, consequently, that the
isomers that arise from such asymmetry are included within the scope of the invention, unless otherwise indicated.
Such isomers can be obtained in substantially pure form by classical separation techniques and stereochemically controlled synthesis. The compounds of this invention can exist in stereoisomeric form, therefore, they can be produced as individual stereoisomers or as mixtures. "Isomerism" means compounds that have identical molecular formulas but that differ in the nature or sequence of the bonds of their atoms or in the arrangement of their atoms in space. The isomers that differ in the arrangement of their atoms in space are called "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers", and stereoisomers that are non-superposable mirror images are referred to as "enantiomers" or sometimes optical isomers. A carbon atom attached to four non-identical substituents is termed a "chiral center". "Chiral isomer" means a compound with at least one chiral center. It has two enantiomeric forms of opposite chirality and can exist as a single enantiomer or as a mixture of enantiomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture". A compound that has more than one chiral center has 2n_1 enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center can exist as an individual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture". When a chiral center is present, a stereoisomer can be characterized by the absolute configuration (R or S) of that
chiral center. The absolute configuration refers to the arrangement in the space of the substituents attached to the chiral center. The substituents attached to the chiral center under qualification are classified according to the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al, Angew, Chem., Inter .: Edit 1966, 5, 385, Errata 511, Cahn et al., Angew, Chem. 1966, 78, 413, Cahn and Ingold, J. Chem. Soc. 1951 (London ), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J., Chem. Educ. 1964, 41, 116). "Geometric isomers" mean the diastereomers that owe their existence to the impeded rotation around the double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same side or the opposite of the double bond in the molecule, according to the rules of Cahn-Ingold- Prelog. In addition, the structures and other compounds discussed in this application include all atropic isomers thereof. "Atropic isomers" are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. The atropic isomers owe their existence to the restricted rotation caused by the impediment of the rotation of large groups around a central link. Such atropic isomers typically exist as a mixture, however, as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in selected instances. The terms "crystalline polymorphs" or "polymorphs" or "crystalline forms" mean crystalline structures in which a compound (or salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different
Crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and solubility. The solvent of recrystallization, the speed of crystallization, the storage temperature and other factors can cause a crystalline form to dominate. The crystalline polymorphs of the compounds can be prepared by crystallization under different conditions. In addition, the compounds of the present invention, for example, the salts of the compounds, can exist in hydrated or unhydrated form (the anhydrous form) or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc. "Solvates" means solvent addition forms that contain stoichiometric or non-stoichiometric amounts of the solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. The hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water maintains its molecular status as H20, such a combination is capable of forming one or more hydrates. "Tautomers" refers to compounds whose structures differ markedly in the arrangement of atoms, but which exist in a quick and easy equilibrium. It will be understood that the compounds of Formula I can be described
as different tautomers. It should also be understood that when the compounds have tautomeric forms, all tautomeric forms are intended to be within the scope of the invention, and the nomenclature of the compounds does not exclude any tautomeric form. Some compounds of the present invention may exist in a tautomeric form, which is also intended to be encompassed within the scope of the present invention. The compoundsSalts and prodrugs of the present invention can exist in various tautomeric forms, including the enol and imine form, and the keto and enamine form and the geometric isomers and mixtures thereof. All such tautomeric forms are included within the scope of the present invention. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually a tautomer predominates. Although a tautomer can be described, the present invention includes all tautomers of the compounds present. A tautomer is one of two or more structural isomers that exist in equilibrium and are easily converted from one isomeric form to another. This reaction results in the formal migration of a hydrogen atom accompanied by a change in the adjacent conjugated double bonds. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be achieved. The exact ratio of tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible through tautomerizations is called tautomerism. Of the various types of tautomerism that are possible, two are commonly observed. In the keto-enol tautomerism,
a simultaneous displacement of electrons and a hydrogen atom occurs. Ring-chain tautomerism is exhibited by glucose. It arises as a result of the aldehyde group (-CHO) in the sugar chain molecule that reacts with one of the hydroxy groups (-0H) in the same molecule to give it a cyclic form (ring shape). The tautomerizations are catalysed by: Base: 1. deprotonation; 2. formation of a delocalized anion (for example, an enolate); 3. protonation in a different position of the anion; Acid: 1. protonation; 2. formation of a delocalised cation; 3. deprotonation in a different position adjacent to the cation. The common tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactimate, amide-imide acid, tautomerism in heterocyclic rings (for example, in the nucleobases guanine, thymine and cytosine), amine-enamine and enamine-enamine. Examples include:
As used herein, the term "analogue" refers to a chemical compound that is structurally similar to another, but differs slightly in composition (as in the replacement of an atom with an atom of a different element or in the presence of a particular functional group, or
the replacement of a functional group by another functional group).
Thus, an analog is a compound that is similar or comparable in function and appearance, but is not structure or origin to the reference compound. As defined herein, the term "derivative" refers to compounds that have a common core structure, and are substituted with various groups as described herein. For example, all the compounds represented by the formula I are indole derivatives, and have the formula I as a common nucleus. The term "bioisostere" refers to a compound that results from the exchange of an atom or a group of atoms with another atom or group of atoms widely similar. The purpose of a bioisostomeric replacement is to create a new compound with biological properties similar to the original compound. The bioisostic replacement can be based physico-chemical or topological. Examples of bioisosteres of carboxylic acids include acyl sulfonimides, tetrazoles, sulfonates and phosphonates. See, for example, Patani and LaVoie, Chem. Rev. 96, 3147-3176 (1996). The phrases "parenteral administration" and "parenterally administered" are terms recognized in the art, and include modes of administration other than enteral and topical administration, such as injections, and include, but are not limited to, intravenous, intramuscular injection and infusion, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal. The term "treat" is recognized in the art and
it includes inhibiting a disease, disorder or condition in a subject, for example, preventing its progress; and alleviating the disease, disorder or condition, for example, causing the regression of the disease, disorder and / or condition. The treatment of the disease or condition includes alleviating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected. The term "prevent" is recognized in the art and includes stopping a disease, disorder or condition occurring in a subject, which may be predisposed to the disease, disorder and / or condition, but which has not been diagnosed as having it. Preventing a condition related to a disease includes stopping the condition from occurring after the disease has been diagnosed, but before the condition has been diagnosed. A "pharmaceutical composition" is a formulation that contains the described compounds in a form suitable for administration to a subject. In a preferred embodiment, the pharmaceutical composition is in a bulk or unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump in an aerosol inhaler or a vial. The amount of the active ingredient (eg, a formulation of the described compound or salts thereof) in a unit dose of the composition, is an effective amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage, depending on the age and condition of the patient. The dosage will also depend on the route of
administration. A variety of tuts are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal and the like. Dosage forms for topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In a preferred embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any required preservatives, buffers or propellants. The term "instantaneous dose" refers to formulations of the compound which are rapidly dispersing dosage forms. The term "immediate release" is defined as a release of a compound from a dosage form in a relatively short period of time, generally up to about 60 minutes. The term "modified release" is defined to include delayed release, extended release and pulse release. The term "pulse release" is defined as a series of drug releases from a dosage form. The term "sustained release" or "extended release" is defined as the continuous release of a compound from a dosage form over a prolonged period. The phrase "pharmaceutically acceptable" is recognized in the art. In certain embodiments, the term includes compositions, polymers and other materials and / or dosage forms that are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals, without excessive toxicity,
irritation, allergic response or other problem or complication, commensurate with a reasonable benefit / risk ratio. The phrase "pharmaceutically acceptable carrier" is recognized in the art, and includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any composition from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of a composition and not harmful to the patient. In certain embodiments, a pharmaceutically acceptable carrier is non-pyrogenic. Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) damping agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) solutions buffered with phosphate and (21) other non-toxic compatible substances
used in pharmaceutical formulations. The compounds of the invention are also capable of forming salts. All these forms are also contemplated within the scope of the claimed invention. "Pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. For example, the salt can be an acid addition salt. One embodiment of an acid addition salt is a hydrochloride salt. The pharmaceutically acceptable salts of the present invention can be synthesized from an original compound containing a basic or acidic portion, by conventional chemical methods. Generally, such salts can be prepared by reacting the acid or free base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of two.; Generally, a non-aqueous medium such as ether, ethyl acetate, isopropanol or acetonitrile is preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990). For example, the salts may include, but are not limited to, the hydrochloride and acetate salts of the aliphatic, amine-containing, hydroxyl-containing, amine-containing, and imine-containing hydroxyl of the present invention. It should be understood that all references to pharmaceutically acceptable salts include the solvent addition forms (solvates) or crystalline forms (polymorphs) as defined herein, of the same salt. The compounds of the present invention can also be prepared as esters, for example, esters
pharmaceutically acceptable For example, a group with a carboxylic acid function in a compound can be converted to its corresponding ester, for example, a methyl, ethyl and other ester. Also, an alcohol group in a compound can be converted to its corresponding ester, for example, an ester of acetate, propionate or other ester. The compounds of the present invention can also be prepared as prodrugs, for example, pharmaceutically acceptable prodrugs. The terms "pro-drugs" and "prodrugs" are used interchangeably herein and refer to any compound that releases an original active drug in vivo. Since it is known that prodrugs improve numerous desirable qualities of pharmaceutical products (eg, solubility, bioavailability, manufacture, etc.), the compounds of the present invention can be delivered in the form of a prodrug. Thus, the present invention aims to cover the prodrugs of the currently claimed compounds, the methods for supplying them and the compositions containing them. "Prodrugs" are intended to include any covalently linked carriers that release the active parent drug of the present invention in vivo, when such a prodrug is administered to a subject. The prodrugs of the present invention are prepared by modifying the functional groups present in the compound, such that the modifications are cleaved, either by routine manipulation or in vivo, to the original compound. Prodrugs include the compounds of the present invention, wherein a hydroxy, amino, sulfhydryl, carboxy or carbonyl group is attached to any group that can be cleaved in vivo, to form a free hydroxyl group, free amino, free sulfhydryl, free carboxy or
carbonyl free, respectively. Examples of prodrugs include, but are not limited to, esters (e.g., acetate derivatives, dialkylaminoacetates, formates, phosphates, sulfates, and benzoate) and carbamates (e.g., N, N-dimethylaminocarbonyl) of hydroxy functional groups, ester groups ( for example, ethyl esters, morpholinoethanol esters) of carboxyl functional groups, N-acyl derivatives (e.g., N-acetyl) bases of N-Mannich, Schiff bases and enaminones of amino functional groups, oximes, acetals, ketals and enol esters of the ketone and aldehyde functional groups in the compounds of Formula I, and the like. See, Bundegaard, H.
"Design of Prodrugs" p 1-92, Elesevier, New York-Oxford (1985). "Protective group" refers to a grouping of atoms that, when bound to a reactive group in a molecule, masks, reduces or prevents that reactivity. Examples of protecting groups can be found in Green and Uts, Protective Groups in Organic Chemistry, (ile, 2nd ed., 1991); Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996); and Kocienski, Protecting Groups, (Verlag, 3rd ed., 2003). The term "amine protecting group" is intended to mean a functional group that converts an amine, amide or other nitrogen-containing portion to a different chemical group that is substantially inert to the conditions of a particular chemical reaction. The amine protecting groups are preferably, easily and selectively removed in good yield under conditions that do not affect other functional groups of the molecule. Examples of amine protecting groups include, but are not limited to, formyl, acetyl, benzyl, t-butyldimethylsilyl, t-groups.
butyldiphenylsilyl, t-butyloxycarbonyl (Boc), p-methoxybenzyl, methoxymethyl, tosyl, trifluoroacetyl, trimethylsilyl (TMS), fluorenyl-methyloxycarbonyl, 2-trimethylsilyl-ethoxycarbonyl, 1-methyl-1- (4-biphenylyl) ethoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl (CBZ), 2-trimethylsilyl-ethanesulfonyl (SES), substituted triphenyl and triflyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratriloxycarbonyl (NVOC), and the like. Other suitable amine protecting groups are directly identified by those skilled in the art. Representative hydroxy protecting groups include those in which the hydroxy group is acylated or alkylated, such as benzyl and triphenyl ethers, as well as alkyl ethers of tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers. The term "pharmaceutically acceptable salts" is recognized in the art, and includes relatively non-toxic inorganic and organic acid addition salts, compositions, including non-exclusively, therapeutic agents, excipients, other materials, and the like. Examples of pharmaceutically acceptable salts include those derived from mineral acids, such as hydrochloric acid and sulfuric acid, and those derived from organic acids, such as ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like. Examples of inorganic bases suitable for the formation of salts include the hydroxides, carbonates and bicarbonates of ammonium, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc and the like. The salts can also be formed with suitable organic bases, including those that are not toxic and strong enough to form such salts. For purposes of illustration, the class of such organic bases
they may include mono, di and trialkylamines, such as methylamine, dimethylamine and triethylamine; mono, di or trihydroxyalkylamines such as mono, di and triethanolamine; amino acids, such as arginine and lysine; guanidine; N-methylglucosamine; N-methylglucamine; L-glutamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; (trihydroxymethyl) aminoethane; and the similar. See, for example, J. Pharm. Sci. 66: 1-19 T1977. A "patient", "subject" or "host" to be treated by the method can mean any human or non-human animal, such as primates, mammals and vertebrates. The term "prophylactic or therapeutic" treatment is recognized in the art, and includes administration to the host of one or more of the compositions. If it is administered before the clinical manifestation of the unwanted condition (eg, the disease or other unwanted state of the host animal), then the treatment is prophylactic, that is, it protects the host against the development of the undesired condition, whereas if it is administered after the manifestation of the undesired condition, the treatment is therapeutic (that is, it is intended to decrease, reduce or stabilize the undesired existing condition or the side effects thereof). The terms "therapeutic agent", "drug", "medicament" and "bioactive substance" are recognized in the art, and include molecules and other agents that are biologically, physiologically or pharmacologically active substances that act locally or systemically in a patient or subject to treat a disease or condition, such as macular degeneration or other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin. The
terms include, but are not limited to, pharmaceutically acceptable salts thereof and prodrugs. Such agents can be acidic, basic or salts; they can be neutral molecules, polar molecules or molecular complexes capable of forming hydrogen bonds; they can be prodrugs in the form of ethers, esters, amides and the like, which are biologically activated when administered to a patient or subject. The phrase "therapeutically effective amount" is a term recognized in the art. In certain embodiments, the term refers to an amount of a therapeutic agent when incorporated into a polymer, produces some desired effect at a reasonable benefit / risk ratio applicable to any medical treatment. In certain embodiments, the term refers to a quantity necessary or sufficient to eliminate, reduce or maintain (e.g., prevent the spread of) a tumor or other objective of a particular therapeutic regimen. The effective amount may vary depending on factors such as the disease or condition being treated, the particular constructs selected being administered, the size of the subject or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular compound without undue experimentation. In certain embodiments, a therapeutically effective amount of a therapeutic agent for in vivo use will likely depend on several factors, including: the rate of release of an agent from a polymer matrix, which will depend in part on the chemical and physical characteristics of the polymer; the identity of the agent; the mode and method of administration; and any other materials incorporated in
the polymer matrix in addition to the agent. The term "ED50" is recognized in the art. In certain embodiments, ED50 means the dose of a drug that produces 50% of its response or maximum effect, or alternatively, the dose that produces a predetermined response in 50% of the subjects or test preparations. The term "LD50" is recognized in the art. In certain embodiments, LD50 means the dose of a drug that is lethal in 50% of the test subjects. The term "therapeutic index", is a term recognized in the art, which refers to the therapeutic index of a drug, defined as LD50 / ED50. The term "substituted", as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection of the indicated group, provided the normal valence of the designated atom is not exceeded, and that the substitution results in a stable compound. When the substituent is keto (ie, = 0), then 2 hydrogens in the atom are replaced. The double bonds in the ring, as used herein, are double bonds that are formed between two adjacent ring atoms (eg, C = C, C = N or N = N). With respect to any chemical compounds, the present invention is intended to include all isotopes of the atoms appearing in the present compounds. Isotopes include those atoms that have the same atomic number but differ in mass numbers. By way of general example and non-exclusively, the isotopes of hydrogen include tritium and deuterium, and the carbon isotopes include C-13 and C-14. The chemical compounds described herein may have asymmetric centers. The compounds of the
present invention containing an asymmetrically substituted atom, can be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by the resolution of racemic forms or by the synthesis of optically active raw materials. Many geometric isomers of olefins, C = N double bonds, and the like, may also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. The cis and trans geometric isomers of the compounds of the present invention are described and can be isolated as a mixture of isomers or as separate isomeric forms. All chiral, diastereomeric, racemic and geometric isomeric forms of a structure are intended, unless the specific stereochemistry or an isomeric form is specifically indicated. All processes used to prepare the compounds of the present invention and the intermediates made herein, where appropriate, are considered part of the present invention. All tautomers of the compounds shown or described as well, where appropriate, are considered part of the present invention. When a bond of a substituent is shown to cross a bond connecting two atoms in a ring, then such a substituent may be attached to any atom in the ring. When a substituent is listed without indicating the atom via which such a substituent is attached to the rest of the compound of a given formula, then such a substituent may be attached via any atom in such a substituent. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.
When an atom or a chemical portion is followed by a numerical range in subscript (for example, Ci-β), the invention is intended to encompass such a number within the range, as well as all intermediate intervals. For example, "Ci-β alkyl" is intended to include alkyl groups with 1, 2, 3, 4, 5, 6, 1-6, 1-5, 1-4, 1-3, 1-2, 2-6 , 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5 and 5-6 carbons. As used herein, "alkyl" is intended to include both a branched (eg, isopropyl, tert-butyl, isobutyl) and straight chain (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl), and cycloalkyl (e.g., alicyclic) groups (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), cycloalkyl groups substituted with alkyl, and alkyl groups substituted with cycloalkyl. Such aliphatic hydrocarbon groups have a specified number of carbon atoms. For example, C? -6 alkyl is intended to include Ci, C2, C3, C4, C5 and C6 alkyl groups. As used herein, "lower alkyl" refers to alkyl groups having from 1 to 6 carbon atoms in the main chain of the carbon chain. "Alkyl" further includes alkyl groups having oxygen, nitrogen, sulfur or phosphorus atoms by replacing one or more carbon atoms of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkyl has six or fewer carbon atoms in its main chain (e.g., Ci-Cß for a straight chain, C3-C6 for a branched chain), e.g., four or less . Similarly, certain cycloalkyls have three to eight carbon atoms in their ring structure, such as five or six atoms in their ring structure. The term "substituted alkyls" refers to
alkyl portions having substituents that replace a hydrogen at one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl , alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. The cycloalkyls can be further substituted, for example, with the substituents described above. An "alkylaryl" or "aralkyl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). As used herein, "alkenyl" is intended to include hydrocarbon chains of straight or branched configuration, having one or more carbon-carbon double bonds occurring at any stable point along the chain. For example, C2_6 alkenyl is intended to include alkenyl groups of C2, C3, C4, C5 and C6. Examples of alkenyl include, but are not limited to, ethenyl and propenyl. As used herein, "alkynyl" is intended to include hydrocarbon chains of straight or branched configuration, having one or more triple carbon-carbon bonds that appear at any stable point throughout the
chain. For example, C2-6 alkynyl is intended to include alkynyl groups of C2, C3, C4, C5 and? . Examples of alkynyl include, but are not limited to, ethynyl and propynyl. In addition, "alkyl", "alkenyl" and "alkynyl" are intended to include portions that are diradical, ie, have two attachment points. A non-limiting example of such an alkyl portion which is a diradical is -CH2CH2-, that is, a C2 alkyl group which is covalently linked via each terminal carbon atom to the rest of the molecule. "Aryl" includes groups with aromaticity, including "non-conjugated" 5 or 6-membered aromatic groups, or of a single ring, which may include from zero to four heteroatoms, as well as "conjugated", or multicyclic, systems with at least one aromatic ring. Examples of aryl groups include benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Furthermore, the term "aryl" includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthyridine, indole, benzofuran, purine, benzofuran , desazapurina or indolizina. These aryl groups having heteroatoms in the ring structure can also be referred to as "aryl heterocycles", "heterocycles", "heteroaryls" or "heteroaromatics". The aromatic ring can be substituted at one or more positions on the ring with substituents such as those described above, such as, for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate,
alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonate, phosphinate, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino
(Including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic moiety or heteroaromatic. The aryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are non-aromatic, to form a multicyclic system (e.g., tetralin, methylenedioxyphenyl). The terms "heterocyclyl" or "heterocyclic group" include closed ring structures, for example, rings from 3 to 10, or 4 to 7 members, which include one or more heteroatoms. "Heteroatom" includes atoms of any element other than carbon or hydrogen. Examples of heteroatoms include nitrogen, oxygen, sulfur and phosphorus. Heterocyclyl groups can be saturated or unsaturated and include pyrrolidine, oxolane, thiolane, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, and sultones. Heterocyclic groups such as pyrrole and furan may have aromatic character. They include fused ring structures such as quinoline and isoquinoline. Other examples of heterocyclic groups include pyridine and purine. The heterocyclic ring can be substituted at one or more positions with substituents such as described above, such
such as halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonate, phosphinate, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety. The heterocyclic groups can also be substituted on one or more constituent atoms with, for example, a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, -CF3, or -CN, or similar. As used herein, "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine. "Contraion" is used to represent a small, negatively charged species such as fluoride, chloride, bromide, iodide, hydroxide acetate and sulfate. "Stable compound" and "stable structure" are intended to indicate a compound that is sufficiently robust to survive the isolation, and as appropriate, the purification of a reaction mixture, and the formulation into an effective therapeutic agent. "Free compound" is used herein to describe a compound in the unbound state. "Extinction coefficient" is a constant used in the Law of Beer-Lambert that is related to the concentration of the substance that is measured (in moles), with the absorbance of
the substance in solution (how well the substance in solution blocks the light that passes in a beam through it so that it comes out the other side). It is an indicator of how much light a compound absorbs at a particular wavelength. In the specification, singular forms also include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as are commonly understood by one of ordinary skill in the art to which the invention pertains. In the case of conflict, this specification will have control. Throughout the description, wherein the compositions are described as having, including or comprising specific components, it is contemplated that the compositions also consist essentially of, or consist of, the exposed compounds. Similarly, where the methods or processes are described as having, including or comprising specific process steps, the processes also consist essentially of, or consist of, the exposed processing steps. In addition, it will be understood that the order of the steps or the order to perform certain actions is not important, as long as the invention remains operable. In addition, two or more steps or actions can be performed simultaneously. "Small molecule" is a recognized term in the art. In certain embodiments, this term refers to a molecule having a molecular weight of less than about 2000 amu, or less than about 1000 amu, and even less than about 500 amu. All the percentages and relationships used in the
present, unless otherwise indicated, are by weight. The "retina" is a region of the central nervous system with approximately 150 million neurons. It is located in the back of the eye, where it rests in a specialized epithelial tissue called retinal pigment epithelium or RPE. The retina initiates the first stage of visual processing, transducing the visual stimuli to specialized neurons called "photoreceptors". Their synaptic outputs are processed by neural networks made in the retina and then transmitted to the brain. The retina has developed two specialized classes of photoreceptors to operate under a wide range of light conditions. The "rod" photoreceptors transduce visual images under low light conditions and mediate achromatic vision. The "cone" photoreceptors transduce visual images in dim light to bright conditions and mediate color vision and high acuity vision. Every photoreceptor is compartmentalized in two regions called the "external" and "internal" segments. The inner segment is the neuronal cell body that contains the cell nuclei. The internal segment survives throughout life in the absence of retinal disease. The outer segment is the region where the light-sensitive visual pigment molecules are concentrated in a dense array of stacked membrane structures. Part of the external segment is released routinely and grows back into a diurnal process, called the renewal of the external segment. The released outer segments are ingested and metabolized by the RPE cells. The "macula" is the central region of the retina that contains the pit, where the visual images are processed
by long thin cones in high spatial detail
("visual acuity"). "Macular degeneration" is a form of retinal neurodegeneration that attacks the macula and destroys the high visual acuity in the center of the visual field. AMD begins in a "dry form", characterized by residual lysosomal granules, called lipofuscin in the cells of the
RPE, and extracellular deposits called "druse". Druse contains cellular waste products excreted by the RPE cells. The "lipofuscin" and the druse can be detected clinically by ophthalmologists and quantified using fluorescent techniques. These may be the first clinical signs of macular degeneration. Lipofuscin contains aggregates of A2E. Lipofuscin accumulates in RPE cells and poisons it by multiple known mechanisms. As the RPE cells become poisoned, their biochemical activities decline and photoreception begins to degenerate. The extracellular druse may further compromise the RPE cells by interfering with their supply of vascular nutrients. Druze also triggers inflammatory processes, which lead to choroidal neovascular invasions of the macula in a patient of ten, progressing to the wet form of AMD. Both the dry form and the wet form progress to blindness. "ERG" is an acronym for electroretinogram, which is the measurement of the potential of the electric field emitted by the neurons of the retina during its response to an experimentally defined luminous stimulus. The ERG is a non-invasive measurement that can be performed on living subjects (human or animal), or on a semi-sectioned eye in solution that has been surgically removed from a live animal. As used herein, the term "RAL"
it means retinaldehyde. The term "RAL collector" means a therapeutic compound that binds to free RAL, and then prevents RAL from forming the condensation of Schiff's base with the phosphatidylethanolamine (PE) of the membrane. "Free RAL" is defined as RAL that is not bound to a protein of the visual cycle. The terms "trans-RAL" and "all trans-RAL" are used interchangeably and mean all trans-retinaldehyde. A2E is a by-product of the reaction of a complex biochemical trajectory called the "visual cycle", which operates collaboratively in the cells of the RPE and the outer segments of the photoreceptor. The visual cycle cycles back to a photoreagent aldehyde chromophore called "retinaldehyde," which is derived from vitamin A, and is essential for vision. In simplified terms, the visual cycle has four main steps: 1) converts vitamin A in the RPE to an aldehyde chromophore with a photoreactive double-stranded bond (11-cis-RAL); 2) transports 11-cis-RAL to the retina, where it binds to a specialized photoreceptor protein called opsin; 3) photoisomerizes light with 11-cis-RAL bound to trans-RAL, which initiates the release of bound RAL from the opsin binding site; 4) converts trans-RAL (an aldehyde) to vitamin A (an alcohol) and transports vitamin A back to the RPE, where the cycle begins again. The trajectory is illustrated in Figure 1, which shows the RPE cells at the top and the outer segments of the photoreceptor below (marked "OS"). The aldehyde group of RAL helps to bind the molecule to opsin, forming a reversible chemical bond to an amino acid side chain at the opsin binding site. Although the aldehyde group in the RAL is essential to anchor the
The molecule in the opsin binding site is otherwise dangerous, due to its propensity to form Schiff bases with other biological amines. The cascade reaction for the formation of A2E is shown in Figure 2. The first three reactions take place in the outer segments of the photoreceptor and produce an intermediate product called A2PE. Once formed, the A2PE is divided into the lipid phase and accumulates in the membranes of the external segment of the photoreceptor. When the RPE cells ingest the discarded outer segments, their accumulated A2PE is routed to their lysosomes. The final reaction of Figure 2 takes place within the lysosomes of the RPE and ends in the formation of A2E. As described above, macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, can be treated or prevented by decreasing the amount of A2E formed. Compounds useful for doing this include the RAL collector. The RAL collectors decrease the amount of A2E formed, for example, forming a covalent bond with the RAL that has escaped the sequestration. The RAL that has reacted with a RAL collector compound is therefore not available to react with the phosphatidyl ethanolamine. Without wishing to stick to a theory, it is thought that the treatment of a patient who has AMD with a RAL collector compound will reduce the rate of A2E formation without limiting the visual cycle speed, thus avoiding the visual deficit of night blindness . In contrast, it is thought that the therapeutic agents for the treatment of AMD that reduce the synthesis of A2E limit the speed of the visual cycle by means of the competitive inhibition of the sites of
retinoid binding of the visual cycle proteins, so that the reduction in the speed of change of the visual cycle, causes a reduction in the speed of formation of the A2E. The present invention reduces the accumulation of A2E without the competitive inhibition of retinoid binding sites in the visual cycle proteins, which is known to cause night blindness. In certain embodiments, a RAL collector is a compound known to form reversible Schiff base adducts with RAL (Figure 3). The RAL collectors of the invention include cyclic amines, as well as cyclic and heterocyclic amines of 5 and 6 members which may have one or more pairs of conjugated double bonds. In one example, the cyclic amines are aromatic. Such compounds include, for example, amines
aromatics, such as benzocaine
procaine
orthocaine MS222 (6)
Tricaine methane sulfonate)
; and anthranilate
of methyl
Heterocyclic compounds include
The useful controls to prove the effectiveness of RAL collectors are lidocaine, a local anesthetic that does not form a Schiff base, thus acting as a negative control; and the darkness that slows down or closes the visual cycle, as a positive control. In one embodiment, the RAL collector compound reacts with the free RAL in a two-step manner to form a stabilized adduct. For example, the RAL and a primary amine of a RAL collector compound condense to form an adduct of a Schiff base, and a reaction of
Internal cyclization forms an uncharged ring containing the nitrogen of the amine. This formation of the ring serves to stabilize the RAL adduct making the dissociation more unfavorably energetic. This prevents free RAL (ie, RAL not bound to opsins or other proteins in the visual cycle) from being available to form the condensation products of Schiff's base with phosphatidylethanolamine and therefore prevents formation of the A2E. In addition, once the ring is closed, it prevents the nitrogen of the amine, now part of the ring, from condensing with a second RAL molecule. It is thought that the reaction of a RAL collector with a second RAL molecule is unfavorable, since such reaction would result in the formation of an adduct having a structure similar to A2E, which has double RAL groups, with castrated tails that they can cause problems of packaging of the lipids in the biological membranes, and therefore detergency of the membrane. In addition, a reaction of the nitrogen of the amine with a second RAL would cause the nitrogen to be charged, which would cause an unfavorable activity, including toxicity, such as poisoning of the lysosomal proton pump in the RPE cells. The compounds useful as the RAL collectors include those according to formula IV:
IV, wherein X is O, N, N (H) or S, het is a 5- or 6-membered heterocycle optionally substituted, n is 0, 1, 2 or 3, and each D is an alkyl group
lower not branched. Each D can be the same or different. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In one embodiment, each D is methyl. In one embodiment, the ring substituents (U) are chosen such that the pKa of the first NH2 ring is about 3.5. Examples include the following annular systems with the pKa in parentheses:
Thiophene (4.1 1) Oxazole (-0.76) Thiazole (0.28)
4-bromobenzyl alcohol (3.82) 4-methanesulfonyl-thiophene (2.26) 4-chloro- (3.96) 4-fluoro- (4.28)
In one embodiment, such compounds react with the RAL according to the mechanism described in Reaction Scheme 1:
The compounds of formula IV,
can be synthesized from the corresponding ester
A description of the reaction between the compound
and the RAL, is presented in Reaction Scheme 2:
Reaction Scheme 2
The compounds of the invention include RAL collectors having a 5 or 6 membered ring. For example, the compounds of the invention retain the
absorption properties of 11-cis-RAL when the two compounds form an adduct of a Schiff base, ie, that adduct formation will not increase the extinction coefficient above that of free 11-cis-RAL nor displace its peak of absorbance at a longer wavelength. Without adhering to a theory, it is thought that this conservation of the absorption properties will minimize the side effects of the treatment in the vision, protecting the 11-cis-RAL from the photoisomerization in the adduct state, thus preserving its chromophore activity, if it dissociates later from the adduct and re-enters the visual cycle, where it will be available to join the opsin in its photoactive state. In certain embodiments, the RAL collector of the invention is a compound having a structure represented by general formula I:
wherein, W, X, Y and Z are each, independently, N, O, S, CU or CH, so that at least one of W, X, Y and Z is N; n is 0, 1, 2, 3 or 4, A is
, D is unbranched lower alkyl, and R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a substituted or unsubstituted, branched alkyl chain , from
C3, C4, C5, Cß, C7 or C8. Each D can be the same or different. Substituents on the alkyl chain of R include a halogen atom; Cl-Cß alkyl optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylamino, lower alkylcarbonylamino, aminosulfonylamino, or lower alkylthio; lower alkylcarbonyl wherein the alkyl portion of the lower alkylcarbonyl is optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylamino, lower alkylcarbonylamino, aminosulfonylamino or lower alkylthio; carbamoyl; or lower alkylthio, wherein the alkyl portion of the lower alkylthio is optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylamino, lower alkylcarbonylamino, aminosulfonylamino or lower alkylthio. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-
β-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino;
(N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In one example, U is aryl, for example benzene.
In certain compounds, A is
and D is methyl,
In certain compounds, U is benzene substituted with halo. In other compounds, two U substituents on adjacent carbon atoms are bonded to form a 5 or 6 membered fused ring. Such rings are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom. In certain compounds, two adjacent U substituents can form a benzene. For example, such fused compounds have the structure:
the
, wherein X, Y and Z are each, independently, N, O, S, CH or absent, so that at least one of X, Y and Z is N; p is 0, 1, 2 or 3, B is a halogen, hydroxyl, carbamoyl, aryl or amino atom, A is
, D is unbranched lower alkyl, and R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a substituted or unsubstituted, branched alkyl chain , of C3, C4, C5, C6, C7 or C8. Examples of the compounds of formula I include pyridine, pyridazine, pyrazine and pyrimidine compounds. The pyridazine compounds include:
the pyrazine compounds
include:
the pyrimidine compounds include:
The compounds of formula I or the include:
In certain embodiments, the RAL collector of the invention is a compound having the structure represented by general formula II or Ha:
wherein, Q, T, and V are each, independently, N, NH, S, O, CU or CH, so that at least one of Q, T and V is not CU or CH; the dotted line represents two double bonds within the ring, which meets the valence requirements of the atoms and heteroatoms present in the ring, m is 0, 1 or 2, A is
, wherein D is unbranched lower alkyl, R is a substituted or unsubstituted, linear alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a substituted or unsubstituted alkyl chain, branched, of C3, C4, C5, C6, C7 or C8. For example, R is C2 alkyl
(ethyl). Substituents on the alkyl chain include a halogen atom; C 1 -C 6 alkyl optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylammo, lower alkylcarbonylammo, aminosulfonylamo or lower alkylthio; lower alkylcarbonyl, wherein the alkyl portion of the lower alkylcarbonyl is optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylamm, lower alkylcarbonylamm, ammonulfonylamine or lower alkylthio; carbamoyl; or lower alkylthio, wherein the alkyl portion of the lower alkylthio is optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, ammo, formylamm, lower alkylcarbonylamine, aminosulfonylamine or lower alkylthio. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-
lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. In one embodiment, for example, U is alkyl. For example, U is methyl, ethyl or propyl. In one embodiment, U is a halogen. For example, U is chlorine, fluorine or bromine. In certain compounds, two U substituents on adjacent carbon atoms are bonded to form a 5 or 6 membered fused ring. Such rings are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom. In one example, U is aryl, for example, benzene.
In certain compounds, A is
, and D is methyl. In certain compounds, U is a benzene substituted with halo. Examples include furan and thiophene compounds,
such as
In certain embodiments, the RAL collector of the invention is a compound having the structure represented by general formula III:
wherein, L is a single bond or CH2; k is 0, 1,
where D is unbranched lower alkyl, R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a branched or unsubstituted alkyl chain, branched, of C3, C4, C5, C6, C7 or C8, k is 0, 1, 2, 3 or 4. Substituents on the alkyl chain include a
halogen atom; C 1 -C 6 alkyl optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylamino, lower alkylcarbonylamino, aminosulfonylamino or lower alkylthio; lower alkylcarbonyl, wherein the alkyl portion of the lower alkylcarbonyl is optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylamino, lower alkylcarbonylamino, aminosulfonylamino or lower alkylthio; carbamoyl; or lower alkylthio, wherein the alkyl portion of the lower alkylthio is optionally substituted with a halogen atom, cyano, hydroxyl, carbamoyl, amino, formylamino, lower alkylcarbonylamino, aminosulfonylamino or lower alkylthio. U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-alkylamino
lower; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino;
(N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. Examples include hydroxylamine compounds and alkyl amines.
In certain compounds, A is
, and D is methyl. In certain compounds, U is a benzene substituted with halo. In other compounds, two U substituents on the adjacent carbon atoms are joined to form a 5 or 6 membered fused ring. Such rings are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom. For example, such fused compounds have the Illa structure:
Illa, where, X, Y and Z are each, independently, N, O, S, CH, CB or is absent, so that at least one of X, Y and Z is N; p is 0, 1, 2 or 3, B is a halogen, hydroxyl, carbamoyl, aryl or amino atom, A is
, D is unbranched lower alkyl, R is a linear or unsubstituted substituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a substituted or unsubstituted, branched alkyl chain, of C3, C4, C5, C6, C7 or C8, and L is a single bond or CH2. In some embodiments, two adjacent U substituents form a 6-membered fused heterocycle, for example, a pyridine ring. In other embodiments, two adjacent U substituents form a 5-membered fused heterocycle. For example, two adjacent U substituents form a thiazole ring. In other embodiments, two adjacent U substituents form an oxazole ring. In other embodiments, two adjacent U substituents form an imidazole ring. Examples of the compounds of formula III or Illa
The reaction of the compound with RAL produces the following conjugate:
Also included are pharmaceutically acceptable addition salts and complexes of the compounds of the formulas given above. In the cases in
where the compounds may have one or more chiral centers, unless specified, the compounds contemplated herein may be a single stereoisomer or racemic mixtures of stereoisomers. The prodrugs, analogues and derivatives thereof are also included.
Methods As discussed above, a described composition can be administered to a subject for the purpose of treating or preventing macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin. Other diseases, disorders or conditions characterized by the accumulation of A2E can be treated in a similar manner. In one embodiment, a compound is administered to a subject, which reduces the formation of A2E. For example, the compound can compete with the PE for the reaction with the trans RAL, thereby reducing the amount of A2E formed. In another embodiment, a compound is administered to a subject, which prevents the accumulation of A2E. For example, the compound competes so successfully with PE by the reaction with trans RAL, that A2E is not formed. Individuals to be treated fall into three groups: (1) those who are clinically diagnosed with macular degeneration or other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, based on visual deficits (including, but not limited to) , adaptation to darkness, sensitivity to contrast and acuity), as determined by visual examination and / or electroretinography and / or retinal health, as indicated by the fundoscopic examination of the retina and the tissue of the
RPE for the accumulation of druse, tissue atrophy and / or fluorescence of lipofuscin; (2) those that are presymptomatic for degenerative macular disease, but are thought to be at risk, based on abnormal results in any or all of the same measures, and (3) those that are presymptomatic but are thought to be at risk genetically, based on family history of degenerative macular disease and / or genotyping results that show one or more alleles or polymorphisms associated with the disease. The compositions are administered topically or systemically one or more times per month, week or day. Dosages can be selected to avoid lateral effects, if any, on visual performance in dark adaptation. The treatment is continued for a period of at least one, three, six, twelve or more months. Patients can be tested at intervals of one, three, six, twelve months or longer to assess safety and efficacy. Efficacy is measured by visual examination and retinal health as described above. In one embodiment, a subject is diagnosed as having symptoms of macular degeneration, and then a described compound is administered. In another embodiment, a subject can be identified as being at risk of developing macular degeneration (risk factors include a history of smoking, age, female gender and family history), and then a described compound is administered. In another embodiment, a subject may have dry AMD in both eyes, and then a described compound is administered. In another embodiment, a subject may have wet AMD in one eye but dry AMD in the other eye, and then a described compound is administered. In yet another modality, a
Subject can be diagnosed as having Stargardt's disease and then a described compound is administered. In another modality, a subject is diagnosed as having symptoms of other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin., and then the compound is administered. In another embodiment a subject can be identified as being at risk of developing other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, and then the compound described is administered. In some embodiments, a compound is administered prophylactically. In some modalities, a subject has been diagnosed as having the disease before the retinal damage is evident. For example, a subject is found to carry a mutation of the gene for ABCA4 and is diagnosed as being at risk for Stargardt disease before any ophthalmological signs are manifest, or a subject is found to have early macular changes indicative of degeneration macular, before the subject realizes any effect on the vision. In some modalities, a human subject may know that he or she is in need of treatment or prevention for macular degeneration. In some modalities, a subject can be monitored for the degree of macular degeneration. A subject can be monitored in a variety of ways, such as by examination of the eye, dilated eye examination, fundoscopic examination, visual acuity test and / or biopsy. Surveillance can be done at various times. For example, a subject can be monitored after a compound is administered. Surveillance can occur, for example, one day, one week, two weeks, one month, two months, six months, one year, two years, five
years or any other period of time after the first administration of the compound. A subject can be monitored repeatedly. In some embodiments, the dose of a compound can be altered in response to surveillance. In some embodiments, the disclosed methods may be combined with other methods to treat or prevent macular degeneration or other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, such as photodynamic therapy. For example, a patient may be treated with more than one therapy for one or more diseases or disorders. For example, a patient may have one eye afflicted with the dry form of AMD, which is treated with a compound of the invention, and the other eye afflicted with the wet form of AMD, which is treated, for example, with therapy photodynamic In some embodiments, a compound for treating or preventing macular degeneration or other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, may be administered chronically. The compound can be administered daily, more than once a day, twice a week, three times a week, weekly, biweekly, monthly, bi-monthly, semi-annually, annually and / or bi-annually. The therapeutic agents can be administered by a wide variety of routes, as described above. In some embodiments, a compound can be administered orally, in the form of a tablet, a capsule, a liquid, a paste and / or a powder. In some embodiments, a compound can be administered locally, such as by intraocular injection. In some embodiments, a compound can be administered systemically in a form
coated, masked or otherwise inactive and activated in the eye (such as by photodynamic therapy). In some embodiments, a compound may be administered in a depot form, so that sustained release of the compound is provided for a period of time, such as hours, days, weeks and / or months. Preferably, the compound is administered topically, as a formulation of eye drops. Typical dose ranges include 0.5 to 5 mg / lOOg for oral formulations and solutions of 0.5% to 5% for eye drops formulations. The compounds of the invention are provided in therapeutic compositions. The compound is present in an amount that is therapeutically effective, which varies widely depending on the particular compound being used. The preparation of the pharmaceutical or pharmacological compositions will be known to those skilled in the art, in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for the solution in, or suspension in a liquid before injection; as tablets or other solids for oral administration; as temporary release capsules or in any other form currently used, including eye drops, creams, lotions, balms, inhalants and the like. The compositions can also be delivered via a microdevice, microparticle or sponge. After formulation, the therapeutic agents will be administered in a manner compatible with the dosage formulation, and in such amount as to be pharmacologically effective. The formulations are easily administered in a variety of dosage forms, such as the type of
injectable solutions described above, but drug release capsules and the like may also be employed. In this context, the amount of the active ingredient and the volume of the composition to be administered depends on the host animal to be treated. The precise amounts of the active compound required for administration depend on the judgment of the practitioner and are peculiar to each individual. A minimum volume of a composition required to disperse the active compounds is typically used. The regimes suitable for administration are also variable, but would be typified by initially administering the compound and verifying the results and then giving additional controlled doses at additional intervals. The amount of the compound incorporated in the composition also depends on the desired release profile, the concentration of the compound required for the biological effect and the time that the biologically active substance has to be released for treatment. In certain embodiments, the biologically active substance can be combined with a polymer matrix at different charge levels, in a room temperature mode and without the need for an organic solvent. In other embodiments, the compositions can be formulated as microspheres. In some embodiments, the compound can be formulated for sustained release. For oral administration in the form of a tablet or capsule (eg, a gelatin capsule), the active drug component can be combined with a non-toxic pharmaceutically acceptable inert oral carrier, such as ethanol, glycerol, water and the like. In addition, when desired or
it is necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, methylcellulose gelatin, sodium carboxymethylcellulose and / or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talc, stearic acid, its magnesium or calcium salt and / or polyethylene glycol. and the similar. The disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, starches, agar, alginic acid or its sodium salt or effervescent mixtures and the like. Diluents include, for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine. The injectable compositions are preferably aqueous isotonic solutions or suspensions, and the suppositories are advantageously prepared from fat emulsions or suspensions. The compositions can be sterilized and / or contain adjuvants, such as preservatives, stabilizers, humectants or emulsifiers, solution promoters, salts for regulating the osmotic pressure and / or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to the conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about
1 to 50%, of the active ingredient. The compounds of the invention can also be administered in oral dosage forms such as tablets or capsules of temporary and sustained release, pills, powders, granules, elixirs, dyes, suspensions, syrups and emulsions. The compounds of the invention can also be administered topically, such as directly to the eye, for example, as eye drops or as an ophthalmic ointment. The drops for the odors typically comprise an effective amount of at least one compound of the invention and a carrier capable of being securely applied to the eye. For example, the eye drops are in the form of an isotonic solution, and the pH of the solution is adjusted so that there is no odor irritation. In many cases, the epithelial barrier interferes with the penetration of molecules into the eye. Thus, currently used ophthalmic drugs are supplemented with some form of penetration enhancer. These penetration enhancers work by loosening the tight joints of the uppermost epithelial cells
(Burstem, 1985, Trans Ophthalmol Soc RU 104 (Pt 4): 402-9;
Ashton et al, 1991, J Pharmacol Exp Ther 259 (2): 719-24; Green et al, 1971, Am J Ophthalmol 72 (5): 897-905). The most commonly used penetration enhancer is benzalcomo chloride (Tang et al, 1994, J Pharm Sci 83 (l): 85-90, Burstein et al, 1980, Invest Ophthalmol Vis Sci 19 (3): 308-13 ), which also works as a conservative against microbial contamination. It is typically applied at a final concentration of 0.01-0.05%.
Selection methods
Suitable compounds can be identified by a variety of screening methods. For example, a candidate compound can be administered to a subject who has or is at risk of developing macular degeneration or other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin, and the accumulation of a retinotoxic compound, such as A2E , it can be measured. A drug that results in a reduced accumulation of a retinotoxic compound, compared to a control (absence of the drug) would be identified as an appropriate drug. Alternatively, RAL and RPE tissue can be analyzed for the presence of A2E and / or its precursors.
EXAMPLES EXAMPLE 1: Synthesis of the Compounds The compounds of the invention, and the related derivatives, can be synthesized by methods known to one of skill in the art. For example, a detailed method for the synthesis of compound 7 is described below in Reaction Scheme 3. Reaction Scheme 3
A mixture of acetonitrile (60 mL) and ethyl 2-amino-1,3, thiazole-4-carboxylate (0.54 g, 3 mmol) and N-fluorobenzenesulfonimide (3.3 g, 9 mmol) was heated to
reflux temperature for 18 hours. The color changed from yellow to reddish. The reaction mixture was concentrated and purified using chromatographic methods: column chromatography (2-5% methanol-chloroform), preparative TLC (2% methanol-chloroform), preparative HPLC (column: Phenomenex Luna phenyl-hexyl (150x4. 6 mm ID, packed at 3 μm), ?? = 215 nm, flow rate: 0.8 mL / minute, injection volume: 5 mL, run time: 31 minutes, gradient of the mobile phase: A: water w 0.1 volume / volume of TFA, B MeCN w 0.1 volume / volume of TFA), and preparative TLC (10% of meOH-chloroform), to give a brown solid (380 mg). LCMS m / z: 145, 173, 191, 381 and 399.? H NMR (300 MHz, CDC13) d: 1.3 ppm (m, 3H Me) and 4.8 ppm (m, 2H, CH2).
EXAMPLE 2: In Vitro Confirmation of the Schiff Base UV / VIS spectroscopy was used to verify the condensation of the Schiff base of the RAL with the primary amine of a compound of the invention. The in vitro analysis of the condensation product of the Schiff base with the RAL was carried out for the compounds described 1, 2, 3, 4, 5 and 6 and the results are shown in Table 1. In the analysis in the solution phase, the max value of the free compound and the condensation product of the RAL and the Schiff base (RAL-SBC) is measured together with the tau value of RAL-SBC. As used herein, "RAL-SBC" means the condensation product of the Schiff base of the RAL and the RAL compound. The solution pass analysis is performed using a 100: 1 mixture of the compound and RAL, using protocols known in the art. Several solvent systems were tested, including aqueous, ethanol, octanol and chloroform: methanol (several, for example, 2: 1). The kinetics of the solution is measured and found to be highly dependent on solvent conditions. Figures 4a and 4b show the results of the condensation of the Schiff base of compound 6 and RAL (100: 1) in chloroform: methanol (2: 1). The solid phase analysis of the condensation of the Schiff base was also performed using a 1: 1 mixture of the compound at RAL. Solid phase analysis was performed using protocols known in the art. The mixture was dried under nitrogen and the condensation reaction occurred until completion. The analysis in lipid phase is carried out using protocols known in the art and measured? Max, tau (RAL-SBC vs. APE / A2PE) and competitive inhibition. The conditions of
Liposomes are closer to in situ conditions.
EXAMPLE 3: Log P and values of pKa The values of log P are shown in Table 1 for compounds 1, 2, 3, 4, 5 and 6. The partition coefficient (log P) is the logarithm of the relationship [ X0rgánico] / [Xacuoso] for a compound X at a pH where X at a pH where X is neutral, not ionized. Values above zero denote lipophilic properties that increase and below zero, hydrophilic properties that increase. Octanol is commonly used as the organic solvent. The examples are as follows: Log P = 2 X is 102 more soluble in the organic solvent than in the aqueous Log P = 0 X is equally soluble in both Log P = -2 X is 102 more soluble in the aqueous solvent than in the organic The log P values are typically calculated algorithmically (not measured experimentally), through programs such as Pallas and ACDlabs. The results of the calculation vary with the product of the program and are considered as approximations of the order of magnitude. The pKa values are shown in Table 1 for compounds 1, 2, 3, 4, 5, 6 and 7. The pKa values are measured using methods known in the art. The acidity of a general acid, HA, is expressed by the chemical equation:
HA + H20 'H30 + + A "
Which is described by the equilibrium constant K. of
According to the general definition of an equilibrium constant, K is expressed as
Because in aqueous solution, [H20] will be constant at 55 mol l "1, that number can be incorporated in a new constant Ka, defined as the acidity constant:
DH30 +] [A-]? A = moles I I [HA]
This measurement, when put on a logarithmic scale, is pka = -logKa. An acid with a pKa less than 1 is defined as strong, one with a pKa greater than 4 is weak. The volume of distribution (V) of a drug can vary widely depending on the pKa of the compound. The volume of distribution is related to the amount of the compound in the body at the concentration of the compound in the blood or plasma.
Table 1.
EXAMPLE: ERG Analysis of Adaptation to Darkness Adaptation to darkness is the recovery of visual sensitivity after exposure to light. The adaptation to the dark has multiple components, including the fast processes (neuronal) and the slow process (photochemical). The regeneration of the visual pigment is related to the slow photochemical process. The dark adaptation speeds are measured for several reasons. Night blindness results from a failure to adapt to darkness (loss of sensitivity to light). It is possible to find a safe dose for night vision by measuring the effects of the drug on the sensitivity to adapted light. An electroretinogram (ERG) is used to measure adaptation to darkness under normal conditions vs. the drug. The ERG is the measurement of the potential of the field
electrical energy emitted by retinal neurons during their response to an experimentally defined luminous stimulus. More specifically, the ERG measures the potentials of the retinal field in the cornea after a flash of light (for example, 50 ms). The field forces are 102 to 103 microvolts, originating in the retinal cells. The ERG is a non-invasive measurement that can be performed on live subjects (human or animal) or on a semi-sectioned eye in solution that has been surgically removed from a live animal. ERG requires general anesthesia that slows down adaptation to darkness and must be factored into an experimental design. In an ERG analysis typical of a dark adaptation experiment, each rat adapts to darkness for hours to reach a consistent state of sensitivity to light. The rat is then "photodecolorated" ie it is briefly exposed to a light strong enough to transiently impoverish the retina of free 11-cis-RAL (eg, 2 minutes at 300 lux). The rat is then returned to darkness immediately to begin adaptation to darkness, ie, recovery of sensitivity to light due to the regeneration of the visual pigment. The ERG is used to measure how quickly the rat adapts to darkness and regains sensitivity to light. Specifically, a variable response criterion is defined for sensitivity to light (see Figure 5). The ERG measurement is taken after a specific duration of a post-discoloration dark recovery (eg, 30 minutes), previously determined by a kinetic analysis (see Figures 6a and 6b). An adjustment of the curve is used to calculate the value for the variable of the
sensitivity. Figure 6a shows the recovery with anesthesia in the same rat, including the dark adaptation kinetics for Y50 and s. A slower adaptation was observed with less sensitivity to light where Y50 reaches -4.0 and tau = 22.6 minutes. Figure 6b shows the recovery without anesthesia (5 different rats), including the kinetics of dark adaptation for Y50. A faster adaptation was observed with more sensitivity to light where Y50 reaches -5.5 and tau = 9.2 minutes. The same paradigm that was described above is followed for the variation of the dose. As shown below in Figure 7, in the dose variation protocol of the ERG, compound 6 i.p. decreases the sensitivity to light of rats adapted to darkness in a dose-dependent manner. The effect on vision decreases after 3 hours.
EXAMPLE 5: NMR Analysis of RAL Reactions NMR spectroscopy was used to verify the formation of Schiff's base condensation and the formation of the RAL ring with the primary amine of a compound of the invention. The EMN analysis of the RAL reactions was performed for the described compounds 6, 8 and 9, as shown in Figure 8 and Table 2. The rates of condensation in the pure chloroform are as follows:
> 8 > 9.
Table 2
EXAMPLE 6: Inhibition of A2E Formation This experiment was designed to establish the proof of concept that the i.p. Chronicity of a RAL collector compound decreases the rate of A2E accumulation in wild type Sprague Dawley rats. These experiments compare the effectiveness of the treatment of the RAL collector compounds with that of the control compounds and the lack of treatment.
Materials and Methods: The study was conducted with wild type Sprague Dawley rats. Groups of treatment rats include, for example, 8 rats of mixed genus by treatment condition. Each animal was treated with one of the following conditions: - Controls: (1) 13-cis retinoic acid to inhibit the retinoid binding sites of the visual cycle proteins as a control protocol, in which such treatment reduces the amount of free trans-RAL that is released and therefore, that is available to form A2E, but with undesirable side effects of night blindness, and (2) a commercially available compound, known clinically to modulate retinal function in humans and known experimentally by forming an adduct of a Schiff base with free RAL, both in animal models in vitro and in vivo. - Vehicle - Compound - Not treated Several compounds are tested, for example, 4 compounds. The compounds are tested through a dose range that includes 1, 5, 15 and 50 mg / kg. The treatment is
administered daily for 8 weeks by i.p injection ..
Chemistry: The experiments use a variety of chemistry services. For example, these experiments use commercially available compounds with analytical specification sheets to characterize the impurities. The compounds are also synthesized. The compounds are prepared in sufficient amounts for the required dosage. The formulations of the compound are suitable for use in initial animal safety studies involving intraperitoneal injection (i.p.). the following three attributes of the reaction product of the Schiff base of the trans-RAL with the compounds of the invention were determined: stability with respect to reaction rates absorption properties, specifically maximum uv-vis absorption and coefficients of extinction (see for example, Figure 5 in Rapp and Basinger, Vision Res. 22: 1097, 1982) or NMR spectrum analysis of reaction kinetics
- solubility values log P and log D, for example, calculated
Biology and Biochemistry: The experiments described here use a variety of biology and biochemistry services. A dose of "no effect level" (NOEL) of the compounds of the invention for the daily treatment with a formulation with eye drops is established, for example, in the rabbit with an ocular irritation protocol and in the rodent with a measurement of ERG from
adaptation to darkness in visual responses to light stimulation. After the treatment and before enucleation of the eye, the following non-invasive tests were performed on the animals, for example, rabbits: - RPE and degeneration of the photoreceptor cells, as is evident from the background photography (Karan, et al. 2005, PNAS 102: 4164) Extracellular drusus and intracellular lipofuscin, as measured by fluorescent background photography (Karan et al 2005) Responses to light are characterized by an ERG (eng, et al, Cell 98:13, 1999) . The concentration of the intracellular A2E of the extracts of the retinal RPE cells is measured in all the treated animals after the conclusion of the treatment protocol using an analytical method, such as those described by Karan et al, 2005; Radu et al, 2003 and Parish et al, PNAS 95: 14609, 1998. For example, in a sample of treated animals, one eye is tested, and the other eye is saved for histological analysis (as described below). In the remaining animals, both eyes are tested separately for the formation of A2E. In post-treatment, the eyes set aside for histology (as described above), the morphology of the retinal tissue and the RPE are evaluated with histology techniques with light microscopy (Karan et al., 2005, with the exception that electron microscopy). it is not used in the experiments described herein). The safety of the treatment regimen is assessed, for example, using a combination of: - Daily documented observation of the animal's behavior and feeding habits throughout the period
of treatment - Visual performance, as measured by the ERG at the end of the treatment period Ocular histology at the end of the treatment period.
Incorporation as Reference All the description of each of the patent documents, including the correction certificates, the patent application documents, the scientific articles, the government reports, the websites and other references in the present, are incorporated as a reference in its entirety for all purposes. In case of a conflict in the terminology, this specification will have control.
Other embodiments Although the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims. It will be understood by those skilled in the art that various changes may be made in the form and details thereof, without departing from the scope of the invention encompassed by the appended claims.
Claims (9)
- CLAIMS: A compound represented by the general formula wherein, X, Y and Z are each, independently, N, S, O, CU or CH, so that at least one of W, X, Y and Z is N; D is unbranched lower alkyl; R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, C6 , C7 or C8; U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are substituted optionally with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; and n is 0, 1, 2, 3 or 4. The compound according to claim 1, wherein the compound comprises a ring of pyridine, pyridazine or pyrazine. The compound according to claim 1, wherein two adjacent U substituents are connected as a benzene ring, forming a compound having the structure according to the formula la: (la), where X, Y and Z are each, independently, N, O, S, CH, or is absent, so that at least one of X, Y and Z is N; p is 0, 1, 2 or 3; B is a halogen, hydroxyl, carbamoyl, aryl or amino atom; A is ; D is unbranched lower alkyl; and R is a linear or substituted unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a substituted or unsubstituted, branched alkyl chain of C3, C4, C5, C6, C7 or C8. 4. The compound according to claim 1, wherein the composition comprises a compound selected from: A compound represented by formula II or l i a (II) or illa), wherein Q, T and V are each, independently, NH, S, 0, CU or CH, so that at least one of Q, T and V is not CU or CH; the dotted line represents two double bonds within the ring, which meets the valence requirements of the atoms and heteroatoms present in the ring; m is 0, 1 or 2; A is D is unbranched lower alkyl; R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, C6 , C7 or C8; and U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more selected heteroatoms of nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-alkylaminocarbonyl lower; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; and 6. The compound according to claim 5, wherein, T and V are selected such that the composition comprises a furan or thiophene ring. 7. A compound represented by general formula III: wherein, L is a single bond or CH2; D is unbranched lower alkyl; R is a linear or unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a branched or unsubstituted, substituted alkyl chain of C3, C4, C5, C6 , C7 or C8; U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are substituted optionally with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; and k is 0, 1, 2, 3 or 4. The compound according to claim 7, wherein two adjacent U substituents are connected as a heterocyclic ring, forming a compound having the structure according to the formula Illa: (Illa), wherein X, Y and Z are each, independently, N, O, S, CB, CH3 or absent, so that at least one of X, Y and Z is N; p is O, 1, 2 or 3; B is a halogen, hydroxyl, carbamoyl, aryl or amino atom; A is D is unbranched lower alkyl; and R is a linear or substituted unsubstituted alkyl chain of Cl, C2, C3, C4, C5, C6, C7 or C8, or a substituted or unsubstituted, branched alkyl chain of C3, C4, C5, C6, C7 or C8. 9. The compound according to claim 8, wherein the fused heterocyclic ring is a 6-membered ring. The compound according to claim 9, wherein the fused heterocyclic ring is a pyridine ring. 11. The compound according to claim 8, wherein the fused heterocyclic ring is a 5-membered ring. The compound according to claim 11, wherein the fused heterocyclic ring is selected from thiazole, oxazole and imidazole.
- 13. A compound of formula IV: (IV), wherein X is O, N (H) or S, het is a 5- or 6-membered heterocycle, "Q n is 0, 1, 2 or 3, and each D is unbranched lower alkyl, U is a substituent selected from a halogen atom; cyano; lower alkyl, wherein one or more hydrogen atoms in the lower alkyl group are optionally substituted with groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms; lower alkylthio, wherein one or more hydrogen atoms in The alkyl group is optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, amino and aryl atom; lower alkylsulfonyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted with groups selected from a halogen atom, 25 hydroxyl, carbamoyl, amino and aryl; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxycarbonyl; carbamoyl; N-lower alkylcarbamoyl; N, N-di-lower alkylaminocarbonyl; Not me; N-lower alkylamino; N, N-di-alkylamino 30 lower; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino) sulfonylamino; (N, N-di-lower alkylamino) sulfonylamino; aryl, optionally substituted with groups selected from a halogen, hydroxyl, carbamoyl, aryl and amino atom; and a monocyclic or bicyclic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen and sulfur atoms. The compound according to claim 13, wherein the first pK a of the NH 2 ring is about 3.5. 2 15 A compound selected from pharmaceutically acceptable salts thereof. 16. The compound according to any of claims 1, 5, 7, 13 and 15, wherein the adduct of the Schiff Base of the compound and the 11-cis-retinaldehyde has an extinction coefficient equal to or less than that of 11- free cis-retinaldehyde. 17. The compound according to claim 16, wherein the absorbance peak of the adduct is at a wavelength equal to or less than that of 11-cis-retinaldehyde. 18. The compound according to any of the claims 1, 5 and 7, wherein A is 19. The compound according to any of the claims 1 and 7, wherein two adjacent U substituents are connected to form a 5 or 6 member ring optionally substituted. 20. The compound according to any of claims 1 and 13, wherein n is selected from 0, 1, 2 or
- 3. 21. The compound according to any of claims 1, 5, 7 and 13, wherein D is unbranched lower alkyl. 22. The compound according to claim 21, wherein D is methyl. 23. The compound according to any of claims 1, 5, 7 and 13, wherein U is aryl. 24. The compound according to claim 23, wherein U is benzene. 25. The compound according to any of claims 1, 5, 7 and 13, wherein U is benzene substituted with halo. 26. The compound according to any of claims 1, 5, 7 and 13, wherein U is alkyl. 27. The compound according to claim 26, wherein U is methyl. 28. The compound according to any of claims 1, 5, 7 and 13, wherein U is halo. 29. The compound according to claim 28, wherein U is fluorine. 30. The compound according to claim 3 or 8, wherein B is aryl. 31. The compound according to claim 30, wherein B is benzene. 32. A pharmaceutical composition comprising a compound according to any one of claims 1, 5, 7, 13 and 15 or a salt, solvate, hydrate or prodrug thereof, and at least one pharmaceutically acceptable excipient. 33. The use of a compound according to any of claims 1, 5, 7, 13 and 15 in the manufacture of a medicament for treating or preventing macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or Lipofuscin in retinal tissue in a subject, the drug reduces the level of accumulation of A2E relative to the level of accumulation of A2E in the subject without the administration of the composition. 34. The use of a compound according to any of claims 1, 5, 7, 13 and 15 in the manufacture of a medicament for diagnosing macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin in the retinal tissue in a bundle. 35. The use of a compound according to any of claims 1, 5, 7, 13 and 15 in the manufacture of a medicament for verifying macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and / or lipofuscin in the retinal tissue in a bundle. 34. The use according to claim 33, wherein the medicament comprises a compound selected from The use according to claim 33, wherein the medicament includes a comp. this selected from benzocaine, procaine, orthocaine, tricaine (MS222) and anthranilate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/685,460 | 2005-05-26 | ||
US60/723,577 | 2005-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007014652A true MX2007014652A (en) | 2008-09-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230041335A1 (en) | Compositions and methods of treating retinal disease | |
JP5815552B2 (en) | Compounds and methods for treating eye diseases | |
WO2016085939A2 (en) | Compounds and methods of treating ocular disorders | |
MX2007014652A (en) | Compositions and methods of treating retinal disease | |
IL145336A (en) | Therapeutic agents for diabetes | |
WO2017085733A2 (en) | Improved process for the synthesis of 2, 6-xylidine and its derivatives | |
AU2017201162A1 (en) | Compounds and methods of treating ocular disorders |